Addex Therapeutics (ADXN)
NASDAQ:ADXN
Want to see ADXN full AI Analyst Report?
Total Valuation
Addex Therapeutics has a market cap or net worth of $6.89M. The enterprise value is $5.23M.
Market Cap$6.89M
Enterprise Value$5.23M
Share Statistics
Addex Therapeutics has 1,822,121 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding1,822,121
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Addex Therapeutics’s return on equity (ROE) is -1.70 and return on invested capital (ROIC) is -65.51%.
Return on Equity (ROE)-1.70
Return on Assets (ROA)-1.27
Return on Invested Capital (ROIC)-65.51%
Return on Capital Employed (ROCE)-0.66
Revenue Per Employee104.07K
Profits Per Employee-3.27M
Employee Count2
Asset Turnover0.03
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Addex Therapeutics is ―. Addex Therapeutics’s PEG ratio is 0.00389.
PE Ratio―
PS Ratio27.51
PB Ratio1.20
Price to Fair Value1.20
Price to FCF-2.76
Price to Operating Cash Flow-2.95
PEG Ratio0.00389
Income Statement
In the last 12 months, Addex Therapeutics had revenue of 208.14K and earned -8.10M in profits. Earnings per share was -6.88.
Revenue208.14K
Gross Profit197.94K
Operating Income-3.39M
Pretax Income-8.24M
Net Income-8.10M
EBITDA-3.38M
Earnings Per Share (EPS)-6.88
Cash Flow
In the last 12 months, operating cash flow was -2.16M and capital expenditures 0.00, giving a free cash flow of -2.16M billion.
Operating Cash Flow-2.16M
Free Cash Flow-2.16M
Free Cash Flow per Share-1.19
Dividends & Yields
Addex Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.62
52-Week Price Change-16.79%
50-Day Moving Average6.65
200-Day Moving Average7.87
Relative Strength Index (RSI)52.76
Average Volume (3m)16.10K
Important Dates
Addex Therapeutics upcoming earnings date is May 25, 2026, TBA (Confirmed).
Last Earnings DateApr 30, 2026
Next Earnings DateMay 25, 2026
Ex-Dividend Date―
Financial Position
Addex Therapeutics as a current ratio of 1.40, with Debt / Equity ratio of 0.73%
Current Ratio1.40
Quick Ratio1.40
Debt to Market Cap<0.01
Net Debt to EBITDA0.48
Interest Coverage Ratio-1.16K
Taxes
In the past 12 months, Addex Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Addex Therapeutics EV to EBITDA ratio is -1.22, with an EV/FCF ratio of -1.98.
EV to Sales19.79
EV to EBITDA-1.22
EV to Free Cash Flow-1.98
EV to Operating Cash Flow-1.98
Balance Sheet
Addex Therapeutics has $1.64M in cash and marketable securities with $34.73K in debt, giving a net cash position of $1.61M billion.
Cash & Marketable Securities$1.64M
Total Debt$34.73K
Net Cash$1.61M
Net Cash Per Share$0.88
Tangible Book Value Per Share$5.10
Margins
Gross margin is -4.78%, with operating margin of -1628.25%, and net profit margin of -3892.31%.
Gross Margin-4.78%
Operating Margin-1628.25%
Pretax Margin-3958.46%
Net Profit Margin-3892.31%
EBITDA Margin-1623.35%
EBIT Margin-1628.25%
Analyst Forecast
The average price target for Addex Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast-55.97%
EPS Growth Forecast-198.81%